Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Food Ingredients Chin... Food Ingredients China
Not Confirmed
Not Confirmed
17-19 March, 2026
RNA Leaders EuropeRNA Leaders Europe
Not Confirmed
Not Confirmed
17-19 March, 2026
Rare Disease SummitRare Disease Summit
Not Confirmed
Not Confirmed
17-19 March, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Food Ingredients China
Not Confirmed
Contact SupplierFood Ingredients China
Food Ingredients Chin... Food Ingredients China
Industry Trade Show
Not Confirmed
17-19 March, 2026
RNA Leaders EuropeRNA Leaders Europe
Industry Trade Show
Not Confirmed
17-19 March, 2026
Rare Disease SummitRare Disease Summit
Industry Trade Show
Not Confirmed
17-19 March, 2026
Digital content
NEWS #PharmaBuzz
07 Jul 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/07/07/3111023/0/en/Mustang-Bio-Granted-Orphan-Drug-Designation-by-U-S-FDA-for-MB-101-IL13Ra2-targeted-CAR-T-cells-to-Treat-Astrocytomas-and-Glioblastoma.html
05 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/05/3037777/0/en/Mustang-Bio-Regains-Compliance-with-Nasdaq-Capital-Market-Requirement.html
27 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/27/3034325/0/en/Mustang-Bio-Announces-Sale-of-Fixed-Assets-and-Exit-of-Facility.html
11 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/11/3024607/0/en/Mustang-Bio-Regains-Compliance-with-Nasdaq-Minimum-Bid-Price-Requirement.html
10 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/10/3023401/0/en/Mustang-Bio-Announces-Closing-of-8-Million-Public-Offering.html
06 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/06/3021896/0/en/Mustang-Bio-Announces-Pricing-of-8-Million-Public-Offering.html
Drugs in Development
Details:
Mustang Bio MB-101 (IL13Ra2-targeted CAR T-cells) is being evaluated for the treatment of recurrent diffuse and anaplastic astrocytoma (astrocytomas) and glioblastoma.
Lead Product(s): MB-101
Therapeutic Area: Oncology Brand Name: MB-101
Study Phase: Phase IProduct Type: Cell & Gene Therapy
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 07, 2025
FDA Grants Orphan Drug Status To Mustang’s MB-101 CAR-T For Brain Cancers
Details : Mustang Bio MB-101 (IL13Ra2-targeted CAR T-cells) is being evaluated for the treatment of recurrent diffuse and anaplastic astrocytoma (astrocytomas) and glioblastoma.
Product Name : MB-101
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
July 07, 2025
Details:
FDA has granted orphan drug designation to Mustang for MB-108, a herpes simplex virus type 1 (HSV-1) oncolytic virus, for the treatment of malignant glioma.
Lead Product(s): MB-108
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 07, 2024
Mustang Bio Granted Orphan Drug Status for MB-108 in Treating Malignant Glioma
Details : FDA has granted orphan drug designation to Mustang for MB-108, a herpes simplex virus type 1 (HSV-1) oncolytic virus, for the treatment of malignant glioma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 07, 2024
Details:
MB-106 is a personalized CD20-targeted, 3rd-generation autologous CAR T-cell therapy. It is being evaluated for the treatment of Waldenstrom macroglobulinemia.
Lead Product(s): MB-106
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Cell & Gene Therapy
Sponsor: Fred Hutchinson Cancer Center
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 17, 2024
Lead Product(s) : MB-106
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Fred Hutchinson Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Mustang Bio: Positive Data from Waldenstrom Macroglobulinemia CAR-T Trial
Details : MB-106 is a personalized CD20-targeted, 3rd-generation autologous CAR T-cell therapy. It is being evaluated for the treatment of Waldenstrom macroglobulinemia.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
June 17, 2024
Details:
MB-106 is a personalized CD20-targeted, 3rd-generation autologous CAR T-cell therapy. It is being evaluated for the treatment of autoimmune diseases.
Lead Product(s): MB-106
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Cell & Gene Therapy
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 28, 2024
Lead Product(s) : MB-106
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Mustang Bio Announces Vision for Expanding CAR T-Cell Platform into Autoimmune Diseases
Details : MB-106 is a personalized CD20-targeted, 3rd-generation autologous CAR T-cell therapy. It is being evaluated for the treatment of autoimmune diseases.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 28, 2024
Details:
MB-109 is Mustang’s designation for the treatment regimen combining MB-101 (COH-developed IL13Rα2‐targeted CAR-T cell therapy) with MB-108 (Nationwide-developed HSV-1 oncolytic virus), which is investigated for Recurrent Glioblastoma and High-Grade Astrocytoma.
Lead Product(s): MB-101,MB-108
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Cell & Gene Therapy
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 26, 2023
Lead Product(s) : MB-101,MB-108
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MB-109 is Mustang’s designation for the treatment regimen combining MB-101 (COH-developed IL13Rα2‐targeted CAR-T cell therapy) with MB-108 (Nationwide-developed HSV-1 oncolytic virus), which is investigated for Recurrent Glioblastoma and High-Grade ...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
October 26, 2023
Details:
MB-106, a first-in-class CD20-targeted, autologous CAR-T cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia.
Lead Product(s): MB-106
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Cell & Gene Therapy
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 16, 2023
Lead Product(s) : MB-106
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MB-106, a first-in-class CD20-targeted, autologous CAR-T cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
August 16, 2023
Details:
Under the agreement, uBriGene gains access to all of Mustang’s assets primarily relating to the manufacturing and production of cell and gene therapies, including MB-106, a first-in-class CD20-targeted autologous CAR T therapy.
Lead Product(s): MB-106
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Cell & Gene Therapy
Sponsor: uBriGene
Deal Size: $11.0 million Upfront Cash: $6.0 million
Deal Type: Agreement July 31, 2023
Lead Product(s) : MB-106
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : uBriGene
Deal Size : $11.0 million
Deal Type : Agreement
Details : Under the agreement, uBriGene gains access to all of Mustang’s assets primarily relating to the manufacturing and production of cell and gene therapies, including MB-106, a first-in-class CD20-targeted autologous CAR T therapy.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : $6.0 million
July 31, 2023
Details:
MB-106 (CD20-targeted autologous CAR T Cell Therapy) which plays a role in the differentiation of B-cells into plasma cells for patients with follicular lymphoma.
Lead Product(s): MB-106
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Cell & Gene Therapy
Sponsor: Fred Hutchinson Cancer Center
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 15, 2023
Lead Product(s) : MB-106
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Fred Hutchinson Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MB-106 (CD20-targeted autologous CAR T Cell Therapy) which plays a role in the differentiation of B-cells into plasma cells for patients with follicular lymphoma.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
June 15, 2023
Details:
MB-106 (CD20-targeted autologous CAR T Cell Therapy) which plays a role in the differentiation of B-cells into plasma cells for patients with Waldenstrom macroglobulinemia.
Lead Product(s): MB-106
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Cell & Gene Therapy
Sponsor: Fred Hutchinson Cancer Center
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 12, 2023
Lead Product(s) : MB-106
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Fred Hutchinson Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MB-106 (CD20-targeted autologous CAR T Cell Therapy) which plays a role in the differentiation of B-cells into plasma cells for patients with Waldenstrom macroglobulinemia.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
June 12, 2023
Details:
MB-106, first-in-class CD20-targeted, autologous CAR T cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas (“BNHL”) and chronic lymphocytic leukemia.
Lead Product(s): MB-106
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Cell & Gene Therapy
Sponsor: The Division of Cancer Treatment and Diagnosis
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 06, 2022
Lead Product(s) : MB-106
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : The Division of Cancer Treatment and Diagnosis
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MB-106, first-in-class CD20-targeted, autologous CAR T cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas (“BNHL”) and chronic lymphocytic leukemia.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
October 06, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
